TAT-P110 是一种抑制 Drp1-Fis1 互作的肽抑制剂，可在多种神经退行性疾病、缺血和败血症模型中减少病理改变，同时不干扰 Drp1 的正常生理功能。

Dynamin-related GTPase DRP1 partial inhibitor (IC50 = 1.2 μM). Selective for DRP1 over other dynamin-related GTPases, OPA1 and DYN1. Increases mitochondrial DNA levels in mfn1- knockout MEFs deficient in mitochondrial fusion. Mallat et al (2018) Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1. Biochem.Biophys.Res.Commun. 499 556 PMID:29601815

DRP1i27是一种有效抑制人源Drp1(动力蛋白相关蛋白1)的化合物。它通过与Drp1的GTPase位点结合，并与Gln34及Asp218形成氢键来发挥作用。DRP1i27主要针对Drp1介导的线粒体裂变细胞系模型，能有效防止模拟缺血再灌注引起的损伤。

Ellipticine quinone, also known as NSC-383230, is a Drp1 inhibitor. rpitor1 and Drpitor1a inhibited the GTPase activity of Drp1 without inhibiting the GTPase of dynamin 1. Ellipticine quinone showed greater potency than the current std. Drp1 GTPase inhibitor, mdivi-​1, (IC50 for mitochondrial fragmentation are (0.06, and 10 μM, resp.)​. Ellipticine quinone suppressed lung cancer tumor growth in a mouse xenograft model. Ellipticine quinone also inhibited mitochondrial ROS prodn., prevented mitochondrial fission, and improved right ventricular diastolic dysfunction during IR injury.

Cell-permeable version of dynamin inhibitory peptide, an inhibitor of the GTPase dynamin that competitively blocks binding of dynamin to amphiphysin, preventing endocytosis. Reduces NMDA receptor internalization.

Ifebemtinib (BI-853520) 是一种具有口服活性和强效性的粘附斑激酶 (FAK) 抑制剂 (IC50=1 nM)，具有抗肿瘤活性，可抑制恶性胸膜间皮瘤中的球状体形成和原位肿瘤生长，可用于研究乳腺癌和卵巢癌。

OXA-11 (FAK-IN-16) 是一种具有口服活性、选择性粘着斑激酶 (FAK) 抑制剂，具有抗肿瘤活性，抑制磷酸酪氨酸 397 位点的 FAK 磷酸化， 以剂量依赖性方式抑制 TOV21G 肿瘤生长，可用于研究癌症。

ZINC40099027 是特异性黏着斑激酶 （FAK） 激活剂，通过激活黏着斑激酶促进持续性阿司匹林相关胃损伤的胃粘膜修复，通过加速FAK激酶结构域的酶活性来激活人黏着斑激酶，激活细胞 FAK 并促进肠上皮伤口闭合。

AMP-945 是一种粘着斑激酶抑制剂。